Last $13.62 USD
Change Today -0.19 / -1.38%
Volume 728.7K
INFI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (INFI) Snapshot

Open
$14.13
Previous Close
$13.81
Day High
$14.37
Day Low
$13.33
52 Week High
12/9/13 - $18.35
52 Week Low
05/7/14 - $8.40
Market Cap
661.7M
Average Volume 10 Days
487.7K
EPS TTM
$-3.04
Shares Outstanding
48.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INFINITY PHARMACEUTICALS INC (INFI)

infinity pharmaceuticals inc (INFI) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (INFI) Details

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to people with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies and inflammatory diseases. The company is conducting DUOTM, a randomized, monotherapy Phase 3 study of IPI-145 in patients with relapsed/refractory chronic lymphocytic leukemia; an ongoing Phase 1 dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies; a Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of IPI-145 in patients with rheumatoid arthritis; and a Phase 2a trial of IPI-145 in patients with mild allergic asthma, as well as completed a Phase 1 trial of IPI-145 in healthy adult subjects. It also develops IPI-443, an oral inhibitor of PI3K-delta and gamma; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company has strategic collaboration with AbbVie Inc. to develop and commercialize duvelisib (IPI-145) in oncology. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

180 Employees
Last Reported Date: 02/25/14

infinity pharmaceuticals inc (INFI) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $552.0K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $378.8K
President of Research & Development
Total Annual Compensation: $465.8K
Chief Scientific Officer
Total Annual Compensation: $366.4K
Compensation as of Fiscal Year 2013.

infinity pharmaceuticals inc (INFI) Key Developments

Infinity Reports Topline Data from Phase 2a Exploratory Study of Duvelisib in Patients with Mild, Allergic Asthma

Infinity Pharmaceuticals, Inc. announced encouraging topline data from its Phase 2a exploratory study of duvelisib (IPI-145), its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with mild, allergic asthma. Data from this randomized, double-blind, placebo-controlled, cross-over study demonstrated that duvelisib was well tolerated and met several secondary and exploratory endpoints in an allergen challenge study. Clinical improvement was observed in the late-phase asthmatic response FEV(1) (a standard lung function test that measures the amount of air that can be exhaled in one second) among patients who received duvelisib administered at the dose tested, 25 mg twice daily (BID) for five days; however the primary endpoint of the study was not met as it did not reach statistical significance (p = 0.052). Multiple secondary clinical endpoints measuring improvements in lung function following duvelisib administration were achieved with statistical significance and were associated with changes in key cytokines and chemokines involved in the asthmatic response. Taken together, these data demonstrate early proof-of-activity in this allergen challenge study. The Phase 2a, randomized, double-blind, placebo controlled, exploratory study was designed to evaluate the activity and safety of duvelisib in 50 patients with mild, allergic asthma following an inhalational allergen challenge. Patients were randomized to receive treatment with placebo followed by duvelisib or duvelisib followed by placebo in a two-period cross-over design, with duvelisib administered at either 1 mg BID (n = 14) or 5 mg BID for 14 days (n = 18), or 25 mg BID for five days (n = 18). The study included a washout period between the two treatment periods of this cross-over study, in which each patient serves as his own control. The study primary endpoint of significantly improving the maximum early-phase or late-phase asthmatic response as measured by FEV(1) was not met at any of the doses tested. However, clinical improvement in the late-phase response was observed at the 25 mg BID dose (p = 0.052) and multiple secondary efficacy endpoints were significantly positive at the 25 mg BID dose, including an improvement in FEV(1) AUC (area under the curve) over the entire assessment period (p = 0.013) and a decrease in patients' sensitivity to methacholine treatment, a measure of airway hyper-reactivity (p = 0.036). Additionally, the 5 mg BID and 25 mg BID doses of duvelisib significantly decreased serum levels of key mediators of airway inflammation. In the study, duvelisib was well tolerated at all three dose levels studied. No serious adverse events were reported, and there were no clinically significant safety findings. Infinity expects to present the final data in a peer-reviewed setting after all analyses are complete. In addition, the company anticipates determining its next steps for development of PI3K-delta,gamma inhibitors in inflammation after evaluating the results from the ASPIRA study in rheumatoid arthritis, which are expected by the end of 2014.

Infinity Pharmaceuticals, Inc. Enters into a First Amendment to Facility Agreement with Deerfield Management Company, L.P

Infinity Pharmaceuticals, Inc. entered into a first amendment to facility agreement with affiliates of Deerfield Management Company, L.P. to amend that certain facility agreement dated as of February 24, 2014 by and among the company and the lenders. Under the first amendment, the company and the lenders have agreed to reduce the maximum principal amount that the company may draw down under the credit facility established under the facility agreement, subject to the terms and conditions set forth therein, from $100,000,000 to $50,000,000. Accordingly, under the first amendment, the fee owed by the company on February 27, 2015 or upon the earlier termination or acceleration of the credit facility has been reduced from 3% of the then-undrawn portion of the previous $100,000,000 commitment to 3% of the then-undrawn portion of the revised $50,000,000 commitment. To date, the company has not drawn down any portion of funds available to it under the credit facility.

AbbVie Inc., Infinity Pharmaceuticals, Inc. - Special Call

To discuss the Infinity Pharmaceuticals, Inc.'s strategic collaboration with AbbVie Inc

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INFI:US $13.62 USD -0.19

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INFI.
View Industry Companies
 

Industry Analysis

INFI

Industry Average

Valuation INFI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit www.infi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.